Abeona Therapeutics IncNASDAQ:ABEO
- LAST PRICE4.2900
- TODAY'S CHANGE (%)0.0800 (1.9002%)
- Bid / Lots4.2900/ 52
- Ask / Lots4.3000/ 5
- Open / Previous Close4.2200 / 4.2100
- Day Range
- 52 Week Range
- Volume153,916
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ABEO |
|---|---|---|
| 09:32 ET | 4121 | 4.23 |
| 09:36 ET | 1310 | 4.285 |
| 09:38 ET | 300 | 4.2949 |
| 09:39 ET | 194 | 4.29 |
| 09:41 ET | 300 | 4.29 |
| 09:45 ET | 3900 | 4.3401 |
| 09:50 ET | 3644 | 4.3603 |
| 09:52 ET | 5642 | 4.3899 |
| 09:57 ET | 1000 | 4.37 |
| 09:59 ET | 1300 | 4.375 |
| 10:01 ET | 39590 | 4.32 |
| 10:03 ET | 1805 | 4.3 |
| 10:06 ET | 200 | 4.3 |
| 10:10 ET | 100 | 4.29 |
| 10:14 ET | 500 | 4.305 |
| 10:15 ET | 600 | 4.305 |
| 10:17 ET | 675 | 4.305 |
| 10:19 ET | 1711 | 4.31 |
| 10:21 ET | 1074 | 4.33 |
| 10:24 ET | 1300 | 4.325 |
| 10:26 ET | 638 | 4.33 |
| 10:28 ET | 1022 | 4.32 |
| 10:30 ET | 1200 | 4.32 |
| 10:32 ET | 389 | 4.311 |
| 10:33 ET | 100 | 4.305 |
| 10:44 ET | 100 | 4.3 |
| 10:46 ET | 4718 | 4.32 |
| 10:48 ET | 100 | 4.32 |
| 10:50 ET | 100 | 4.3298 |
| 10:51 ET | 19319 | 4.34 |
| 10:57 ET | 2273 | 4.38 |
| 11:00 ET | 1835 | 4.375 |
| 11:02 ET | 3300 | 4.3897 |
| 11:04 ET | 315 | 4.3773 |
| 11:06 ET | 1900 | 4.378 |
| 11:08 ET | 2500 | 4.3601 |
| 11:09 ET | 900 | 4.39 |
| 11:11 ET | 100 | 4.37 |
| 11:20 ET | 200 | 4.37 |
| 11:22 ET | 14540 | 4.35 |
| 11:24 ET | 538 | 4.35 |
| 11:26 ET | 191 | 4.36 |
| 11:27 ET | 2114 | 4.335 |
| 11:29 ET | 409 | 4.3201 |
| 11:33 ET | 528 | 4.33 |
| 11:38 ET | 400 | 4.33 |
| 11:42 ET | 300 | 4.33 |
| 11:45 ET | 1180 | 4.32 |
| 11:47 ET | 100 | 4.32 |
| 11:49 ET | 200 | 4.32 |
| 11:51 ET | 100 | 4.32 |
| 11:54 ET | 5230 | 4.32 |
| 12:02 ET | 6680 | 4.2992 |
| 12:03 ET | 300 | 4.295 |
| 12:05 ET | 1500 | 4.295 |
| 12:07 ET | 200 | 4.29 |
Yesterday
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Abeona Therapeutics Inc. - ABEO, from 16 hours ago by Dow Jones
16 hours ago by Dow JonesDJ Abeona Therapeutics Initiated at Buy by Stifel, from 8:15AM ET on Thursday May 30, 2024 by Dow Jones
8:15AM ET on Thursday May 30, 2024 by Dow Jones
May 28, 2024
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Abeona Therapeutics Inc. - ABEO, from 4:29PM ET on Tuesday May 28, 2024 by Dow Jones
4:29PM ET on Tuesday May 28, 2024 by Dow JonesAbeona Therapeutics to Present at the Jefferies Global Healthcare Conference, from 7:30AM ET on Tuesday May 28, 2024 by Dow Jones
7:30AM ET on Tuesday May 28, 2024 by Dow Jones
May 26, 2024
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Abeona Therapeutics Inc. - ABEO, from 11:18AM ET on Sunday May 26, 2024 by Dow Jones
11:18AM ET on Sunday May 26, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Abeona Therapeutics Inc | 173.4M | -1.3x | --- |
bluebird bio Inc | 170.5M | -1.2x | --- |
Sagimet Biosciences Inc | 172.3M | -4.4x | --- |
Adverum Biotechnologies Inc | 162.1M | -0.8x | --- |
Greenwich Lifesciences Inc | 172.7M | -18.6x | --- |
Galectin Therapeutics Inc | 169.0M | -3.7x | --- |
Company Information
Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing cell and gene therapies for life-threatening diseases. The Company’s lead clinical program is for prademagene zamikeracel (pz-cel), its investigational autologous, COL7A1 gene-corrected epidermal sheets currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company’s fully integrated cell and gene therapy Good Manufacturing Practice (cGMP) manufacturing facility served as the manufacturing site for pz-cel used in its Phase III VIITAL trial and is capable of supporting commercial production of pz-cel upon FDA approval. The Company’s development portfolio also features adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need. The Company’s novel, next-generation AAV capsids are being evaluated to improve tropism profiles for a variety of devastating diseases.
Contact Information
- Headquarters
- 6555 CARNEGIE AVE, 4TH FLOORCLEVELAND, OH, United States 44103
- Phone
- 646-813-4701
- Fax
- 302-655-5049
Executives
- Chairman of the Board
- Michael Amoroso
- Senior Vice President, Head of Research & Clinical Development
- Vishwas Seshadri
- Chief Financial Officer
- Joseph Vazzano
- General Counsel
- Brendan O Malley
- Independent Director
- Leila Alland
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $173.4M |
|---|---|
Revenue (TTM) | $3.5M |
Shares Outstanding | 41.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.51 |
EPS | $-3.20 |
Book Value | $0.56 |
P/E Ratio | -1.3x |
Price/Sales (TTM) | 49.5 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -1,412.20% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
